Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 7, 2014, Pages 903-911

  Zhou, Yue ^a   Ning, Qing ^b   Yu, Dan Ni ^c   Li, Wei Guang ^c   Deng, Jin ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b KEY LABORATORY OF NEW DRUG DELIVERY SYSTEM OF CHINESE MATERIA MEDICA   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

breviscapine; liposome; oral bioavailability; Pluronic P85

Indexed keywords

BREVISCAPINE; CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; POLOXAMER; CARDIOVASCULAR AGENT; FLAVONOID; MICROCAPSULE; MULTIDRUG RESISTANCE PROTEIN; PLURONIC BLOCK COPOLYMER P85;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOLAYER CULTURE; NONHUMAN; PARTICLE SIZE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMICAL PHENOMENA; DRUG DELIVERY SYSTEM; INTESTINE ABSORPTION; METABOLISM; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PERMEABILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CAPSULES; CARDIOVASCULAR AGENTS; CHOLESTEROL; DRUG DELIVERY SYSTEMS; FLAVONOIDS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTESTINAL ABSORPTION; LIPOSOMES; MALE; P-GLYCOPROTEIN; PARTICLE SIZE; PERMEABILITY; PHOSPHATIDYLCHOLINES; POLOXALENE; POLOXAMER; RATS, SPRAGUE-DAWLEY;

EID: 84902540202     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12215     Document Type: Article

References (40)

1. Yiming L, et al. Neuroprotective effects of breviscapine against apoptosis induced by transient focal cerebral ischaemia in rats. J Pharm Pharmacol 2008; 60: 349-355.
2. Lv W, et al. Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats. Int J Pharm 2008; 359: 118-122.
3. Zhong H, et al. Multivesicular liposome formulation for the sustained delivery of breviscapine. Int J Pharm 2005; 301: 15-24.
4. Xiong Z, et al. Protective effects of breviscapine on ischemic vascular dementia in rats. Biol Pharm Bull 2006; 29: 1880-1885.
5. Wang M, et al. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin 2009; 30: 1081-1091.
6. Zhang HY, Ping QN,. Effects of drug transporters on intestinal absorption of breviscapine. J China Pharm Univ 2007; 38: 60-64.
7. Gaymalov ZZ, et al. The effect of the nonionic block copolymer Pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials 2009; 30: 1232-1245.
8. Batrakova EV, et al. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296: 551-557.
9. Batrakova EV, et al. Effect of Pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004; 21: 2226-2233.
10. Batrakova EV, et al. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res 2003; 20: 1581-1590.
11. Yang W, et al. Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice. J Pharm Pharmacol 2012; 64: 190-198.
12. Ling SS, et al. Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats. J Pharm Pharmacol 2009; 61: 445-449.
13. Panwar P, et al. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine 2010; 5: 101-108.
14. Gradauer K, et al. Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties. Int J Nanomedicine 2012; 7: 2523-2534.
15. Choi JS, et al. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004; 57: 313-318.
16. Liang G, et al. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. J Pharm Pharmacol 2007; 59: 661-667.
17. Sun J, et al. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv 2010; 17: 164-170.
18. Parmentier J, et al. In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. Eur J Pharm Biopharm 2010; 76: 394-403.
19. Werle M, Takeuchi H,. Chitosan-aprotinin coated liposomes for oral peptide delivery: development, characterization and in vivo evaluation. Int J Pharm 2009; 370: 26-32.
20. Li C, et al. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. J Pharm Pharmacol 2011; 63: 376-384.
21. Ge QH, et al. Pharmacokinetics and absolute bioavailability of breviscapine in Beagle dogs. Chin J Pharm 2003; 34: 618-620. 632.
22. Xiong F, et al. Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. Int J Pharm 2011; 421: 275-282.
23. Xiong F, et al. Optimized preparation, characterization and biodistribution in heart of breviscapine lipid emulsion. Chem Pharm Bull 2010; 58: 1455-1460.
24. Liu M, et al. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch Pharm Res 2008; 31: 547-554.
25. Fei X, et al. Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J Drug Target 2009; 17: 408-414.
26. Sun WT, et al. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target 2008; 16: 357-365.
27. Kostarelos K, et al. Molecular structure and conformation in phospholipid vesicles sterically stabilized by (tri)-block copolymers investigated by multi-nuclear magnetic resonance techniques. Colloids Surf A 1998; 136: 1-9.
28. Markus J, et al. Effect of PEO-PPO-PEO triblock copolymers on structure and stability of phosphatidylcholine liposomes. Langmuir 1999; 15: 6314-6325.
29. Kabanov AV, et al. Pluronic block copolymer as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82: 189-212.
30. Kabanov AV, et al. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-779.
31. Seeballuck F, et al. The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res 2003; 20: 1085-1092.
32. Batrakova EV, et al. Effects of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res 1998; 15: 850-855.
33. Batrakova EV, et al. Mechanism of Pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001; 299: 483-493.
34. Evers R, et al. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000; 83: 366-374.
35. Li N, et al. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 2009; 379: 131-138.
36. Sun W, et al. Preparation and evaluation of N(3)-O-toluyl-fluorouracil- loaded liposomes. Int J Pharm 2008; 353: 243-250.
37. Samad A, et al. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007; 4: 297-305.
38. Zhong HJ, et al. Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal for mulation. Pharmazie 2005; 60: 475-476.
39. Lv W, et al. Preparation and pharmacokinetics in rabbits of breviscapine unilamellar vesicles. Drug Dev Ind Pharm 2006; 32: 309-314.
40. Bandarkar FS, Vavia PR,. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin. Drug Dev Ind Pharm 2011; 37: 1318-1328.